Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) cannot be endorsed for use within NHS Wales as a symptomatic treatment of focal spasticity of lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury (TBI). |
||
|
||
Medicine details |
||
| Medicine name | clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) | |
| Formulation | Powder for solution for injection | |
| Reference number | 2638 | |
| Indication | Symptomatic treatment of focal spasticity of lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury (TBI) |
|
| Company | Ipsen Ltd | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 25/05/2017 | |